Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -14.37% | -34.27% | -20.67% | -20.42% | -35.42% |
| Total Depreciation and Amortization | 34.41% | 49.52% | 60.21% | 65.87% | 94.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.59% | 3.62% | 23.48% | 35.35% | 51.12% |
| Change in Net Operating Assets | -246.64% | 435.49% | -336.04% | -110.60% | 123.31% |
| Cash from Operations | -80.71% | 10.25% | -29.09% | -30.16% | -18.73% |
| Capital Expenditure | 46.58% | 29.82% | 0.32% | 10.92% | -54.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 46.58% | 29.82% | 0.32% | 10.92% | -54.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.98% | 50,084.57% | 106.67% | 45.86% | 12.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -381.48% | -- | -- | 22.99% |
| Cash from Financing | 9.08% | 54,809.86% | 102.93% | 45.62% | 12.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.38% | 465.15% | -24.41% | 53.76% | 9.17% |
